Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A. et al, (2023), Nat Genet
Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.
Clift AK. et al, (2023), Lancet Digit Health, 5, e571 - e581
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies.
Lythgoe MP. et al, (2023), Lancet Oncol, 24, 963 - 966
Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.
Freeman SD. et al, (2023), Blood
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2023), Nat Commun, 14
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM. et al, (2023), Br J Cancer
Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1.
Sugiyarto G. et al, (2023), J Immunother Cancer, 11
Early phase antitumour clinical trials and palliative medicine.
Virani F. et al, (2023), BMJ Support Palliat Care
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Charles Coombes R. et al, (2023), Nat Commun, 14
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM. et al, (2023), Cancer Cell, 41, 1222 - 1241.e7
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R. et al, (2023), Br J Cancer, 129, 38 - 45